


About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology



Hematology/Oncology

This is a guide to the publications Spherix will produce in 2025/2026. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications

MARKET DYNAMIX

A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.

REALTIME DYNAMIX

A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.

LAUNCH DYNAMIX

Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

PATIENT CHART DYNAMIX

A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmask real patient management patterns and uncovers the "why" behind treatment decisions.

PATIENT VOICE DYNAMIX

An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.

PAYER DYNAMIX

Empowers pharmaceutical companies with forward-looking insights from key payer decision makers - enabling market access, brand, and strategy teams to confidently navigate evolving coverage and reimbursement landscapes, while preparing for potential policy-driven disruptions.

SPECIAL TOPIX

Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit
www.clientportal.spherixglobalinsights.com



2025 & 2026 Dermatology Publications

Alopecia Areata

MARKET DYNAMIX	- Alopecia Areata, US Alopecia Areata, EU5* Alopecia Areata, JP* Alopecia Areata, CH*
LAUNCH DYNAMIX	- Leqselvi (SUN Pharma) in Alopecia Areata, US - Litfulo (Pfizer) in Alopecia Areata, US

Atopic Dermatitis

MARKET DYNAMIX	- Atopic Dermatitis, US Atopic Dermatitis, JP*
REALTIME DYNAMIX	- Atopic Dermatitis, EU5 - Atopic Dermatitis, JP/ CH
LAUNCH DYNAMIX	- Ebglyss (Eli Lilly) in Atopic Dermatitis, US - Nemluvio (Galderma) in Atopic Dermatitis, US - Vtama and Zoryve (Arcutis/ Dermavant) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	Atopic Dermatits, US*

Chronic Spontaneous Urticaria

MARKET DYNAMIX	Chronic Spontaneous Urticaria, US
PATIENT CHART DYNAMIX	Chronic Spontaneous Urticaria, US*
PATIENT VOICE DYNAMIX	Chronic Spontaneous Urticaria, US*

Other Dermatology Indications

MARKET DYNAMIX	- Asthma, US - Prurigo Nodularis, US
LAUNCH DYNAMIX	- Dupixent (Sanofi/Regeneron) in Chronic Spontaneous Urticaria, US - Dupixent (Sanofi/Regeneron) in Chronic Obstructive Pulmonary Disease, US - Remibrutinib (Novartis) in Chronic Spontaneous Urticaria, US - Nemluvio (Galderma) in Prurigo Nodularis, US
SPECIAL TOPI	- Biologic Coordinators Across Dermatology, US - Awareness and Expected Impact of IRA Changes in 2025

Hidradenitis Suppurativa

MARKET DYNAMIX	Hidradenitis Suppurativa, US
REALTIME DYNAMIX	Hidradenitis Suppurativa, EU5
LAUNCH DYNAMIX	- Bimzelx (UCB) in Hidradenitis Suppurativa, US* - Cosentyx (Novartis) in Hidradenitis Suppurativa, US
PATIENT CHART DYNAMIX	Hidradenitis Suppurativa, US*

Plaque Psoriasis

REALTIME DYNAMIX	- Plaque Psoriasis, US - Plaque Psoriasis, EU5
LAUNCH DYNAMIX	- Bimzelx (UCB) in Plaque Psoriasis, US lctrokinra (J&J) in Plaque Psoriasis, US*
PATIENT CHART DYNAMIX	Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	Plaque Psoriasis, US*
SPECIAL TOPI	The Oral Opportunity in Plaque Psoriasis, US

Vitiligo

MARKET DYNAMIX	- Vitiligo, US - Vitiligo, EU5 Vitiligo, JP* Vitiligo, CH*
----------------	---

Cross Specialty

SPECIAL TOPI	Payer Management Strategies, US
--------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPI	Current events on specific interest areas

*Pending approvals and launch

*New in 2026

Publications may change due to factors such as FDA approval status and other market events



Eosinophilic Esophagitis

MARKET DYNAMIX	- Eosinophilic Esophagitis, US - Eosinophilic Esophagitis, EU5 (2025 only)
----------------	---

Inflammatory Bowel Disease

REALTIME DYNAMIX	- Crohn's Disease, US - Crohn's Disease, EU5 - Ulcerative Colitis, US - Ulcerative Colitis, EU5
LAUNCH DYNAMIX	- Tremfya (Janssen) in Crohn's Disease, US - Omvoh (Eli Lilly) in Crohn's Disease, US - Skyrizi (AbbVie) in Ulcerative Colitis, US - Tremfya (Janssen) in Ulcerative Colitis, US
PATIENT CHART DYNAMIX	Inflammatory Bowel Disease New Starts, US⁺ - Inflammatory Bowel Disease Switching, US - Inflammatory Bowel Disease Switching, EU5
PATIENT VOICE DYNAMIX	Inflammatory Bowel Disease, US⁺
SPECIAL TOPIX	The Role of APPs in IBD⁺

Cross Specialty

SPECIAL TOPIX	- Awareness and Expected Impact of IRA Changes in 2025 - Payer Management Strategies, US
---------------	---

MASH

MARKET DYNAMIX	- MASH, US - MASH, EU5 (2025 only)
LAUNCH DYNAMIX	- Rezdiffra (Madrigal) in MASLD/MASH, US (2025 only) - Wegovy (Novo Nordisk) in MASLD/MASH, US
PATIENT CHART DYNAMIX	MASH, US⁺
SPECIAL TOPIX	MASH Screening and Management among PCPs and Endocrinologists, US⁺

Other Gastroenterology Indications

MARKET DYNAMIX	- Celiac Disease, US - Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US
REALTIME DYNAMIX	Irritable Bowel Syndrome, US
LAUNCH DYNAMIX	- Iqirvo (Ipsen) in Primary Biliary Cholangitis, US - Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US
SPECIAL TOPIX	- Biologic Coordinators in Gastroenterology, US The Business of Gastroenterology, US⁺

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



2025 & 2026 Rheumatology Publications

Lupus

MARKET DYNAMIX	- Cutaneous Lupus, US - Systemic Lupus Erythematosus, US - Systemic Lupus Erythematosus Pipeline Refresh, US - Systemic Lupus Erythematosus, EU5 Lupus Nephritis, China⁺
REALTIME DYNAMIX	- Lupus Nephritis, US - Lupus Nephritis, EU5 Lupus Nephritis, Brazil⁺ Lupus Nephritis, Canada⁺
LAUNCH DYNAMIX	Gazyva (Genentech) in Lupus Nephritis, US
PATIENT CHART DYNAMIX	- Lupus Nephritis, US - Moderate to Severe SLE, US Systemic Lupus Erythematosus & Lupus Nephritis, EU5⁺ Cutaneous Lupus, US⁺
PATIENT VOICE DYNAMIX	SLE/LN, US

Other Rheumatology Indications

MARKET DYNAMIX	- Idiopathic Inflammatory Myopathies, US Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA), US⁺ - Rheumatoid Arthritis, US - Rheumatoid Arthritis, EU5 - Systemic Sclerosis, US
LAUNCH DYNAMIX	- Rinvoq (AbbVie) in Giant Cell Arteritis, US Brepocitinib in Dermatomyositis, US⁺⁺ Ianalumab in Sjogren's Disease, US⁺⁺
PATIENT VOICE DYNAMIX	Systemic Sclerosis, US
SPECIAL TOPIX	- Cell Therapy in Rheumatology, US Biologic Coordinators Across Rheumatology, US⁺

Spondyloarthritis (AS, nr-AxSpA, and PsA)

MARKET DYNAMIX	- Ankylosing Spondylitis & nr-AxSpA, US - Ankylosing Spondylitis & nr-AxSpA, EU5 - Psoriatic Arthritis, EU5
REALTIME DYNAMIX	Psoriatic Arthritis, US
LAUNCH DYNAMIX	- Bimzelx (UCB) in AS & nr-AxSpA, US - Bimzelx (UCB) in Psoriatic Arthritis, US Sotyktu (BMS) in Psoriatic Arthritis, US⁺⁺

Cross Specialty

SPECIAL TOPIX	Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



2025 & 2026 Nephrology Publications

Glomerular Diseases

MARKET DYNAMIX	• APOL-mediated kidney disease, US⁺ • Complement Disorders, US⁺ • Fabry's Disease, US⁺ • Focal Segmental Glomerulosclerosis, US⁺ • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), US⁺ • Membranous Nephropathy, US
REALTIME DYNAMIX	• IgA Nephropathy, US • IgA Nephropathy, EU5
LAUNCH DYNAMIX	• Fabhalta (Novartis) in IgAN, US • Vanrafia (Novartis) in IgAN, US • Sibeprenlimab (Otsuka) in IgAN, US* • Fabhalta (Novartis) in C3G, US • Empaveli (Apellis) in C3G, US* • Iptacopan in IgAN- China Deep Dive • Atrasentan in IgAN- China Deep Dive • Sibeprenlimab in IgAN- China Deep Dive • Filispari in FSGS • Vertex-inaxaplin in AMKD
PATIENT CHART DYNAMIX	• Complement 3 Glomerulopathy, US • Focal Segmental Glomerulosclerosis, US • IgA Nephropathy, US • IgA Nephropathy, EU5 • IgA Nephropathy, Japan • IgA Nephropathy, China
PATIENT VOICE DYNAMIX	• IgA Nephropathy, US

Lupus Nephritis

REALTIME DYNAMIX	• Lupus Nephritis, US • Lupus Nephritis, EU5
PATIENT CHART DYNAMIX	• Lupus Nephritis, US

Kidney Disease

MARKET DYNAMIX	• Autosomal Dominant Polycystic Kidney Disease, US
REALTIME DYNAMIX	• Dialysis, US • Dialysis, EU5 • Dialysis, Renal Dietitians, US • Hyperkalemia, US
LAUNCH DYNAMIX	• Xphozah (Ardelyx) in Hyperphosphatemia, US • Vafseo (Akebia) in Renal Anemia, US • OLC (Unicycive) in Hyperphosphatemia, US*
PATIENT CHART DYNAMIX	• Chronic Kidney Disease, Non-Dialysis, US • Dialysis, US
SPECIAL TOPIX	• Multispecialty (Nephrology & Hematology) Approach to Atypical Hemolytic Uremic Syndrome (aHUS), US • Hypertension in CKD, US • Implications of the Dialysis Bundle, US • ASN Kidney Week Conference, US • Buy and Bill in Nephrology Practices, US

Cross Specialty

SPECIAL TOPIX	• Awareness and Expected Impact of IRA Changes in 2025, US • Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Alzheimer's Disease

MARKET DYNAMIX	- Alzheimer's Disease, US: Focus on Diagnostic Pathway (Q2) - Alzheimer's Disease, US: Focus on Pipeline (Q4)
REALTIME DYNAMIX	Alzheimer's Disease, 2 Wave, US⁺
LAUNCH DYNAMIX	- Leqembi (Eisai/Biogen) in Alzheimer's Disease, US - Kisunla (Eli Lilly) in Alzheimer's Disease, US - Semaglutide in Alzheimer's Disease, US
PATIENT CHART DYNAMIX	Alzheimer's Disease, US
PATIENT VOICE DYNAMIX	Alzheimer's Disease, US⁺

Generalized Myasthenia Gravis

REALTIME DYNAMIX	- Generalized Myasthenia Gravis, US Generalized Myasthenia Gravis, EU5⁺
LAUNCH DYNAMIX	- Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US - Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US - Biosimilar eculizumab in Generalized Myasthenia Gravis, US Gefurulumab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US⁺ Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US⁺
PATIENT CHART DYNAMIX	General Myasthenia Gravis, US
PATIENT VOICE DYNAMIX	Generalized Myasthenia Gravis, US⁺

Migraine

REALTIME DYNAMIX	- Migraine, US (2025) Migraine, 2 Wave, US⁺
LAUNCH DYNAMIX	Zavzpret (Pfizer) in Acute Migraine, US
PATIENT CHART DYNAMIX	Migraine, US⁺

Multiple Sclerosis

MARKET DYNAMIX	- Multiple Sclerosis, US: Focus on Current Market Landscape (Q1) - Multiple Sclerosis, US: Focus on Pipeline Opportunities (Q3)
REALTIME DYNAMIX	Multiple Sclerosis, 2 Wave, US⁺
LAUNCH DYNAMIX	Ocrevus Zunovo (Genentech) in Multiple Sclerosis, US⁺

Other Neurology Indications

MARKET DYNAMIX	- Chronic Inflammatory Demyelinating Polyneuropathy, US - Epilepsy, US Huntington's Disease, US⁺ Parkinson's Disease, US⁺
SPECIAL TOPIX	- Neurology Pipeline Opportunities, US - Practice Dynamix in Neurology, US Cell Therapy in Neurology Indications, US⁺

Psychiatric Indications

MARKET DYNAMIX	Bipolar Disease, US⁺ Major Depressive Disorder (MDD), US⁺ Schizophrenia, US⁺
----------------	--

Cross Specialty

SPECIAL TOPIX	Payer Management Strategies, US
---------------	---

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Diabetic Macular Edema

MARKET DYNAMIX	• Diabetic Macular Edema, US⁺
REALTIME DYNAMIX	• <i>Diabetic Macular Edema, US</i>
LAUNCH DYNAMIX	• <i>Pavblu in Diabetic Macular Edema, US</i>
PATIENT CHART DYNAMIX	• <i>Diabetic Macular Edema, US</i>

Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	• <i>Neovascular Age-Related Macular Degeneration, US</i>
LAUNCH DYNAMIX	• <i>Pavblu in Neovascular Age-Related Macular Degeneration, US</i>
PATIENT CHART DYNAMIX	• <i>Neovascular Age-Related Macular Degeneration, US</i>

Other Ophthalmology Indications

MARKET DYNAMIX	• Geographic Atrophy, US • Glaucoma, US • Thyroid Eye Disease (TED), US • Age-Related Macular Degeneration, US⁺ • Diabetic Retinopathy, US⁺ • Dry Eye Syndrome, US⁺ • Glaucoma, US⁺ • Uveitis, US⁺
LAUNCH DYNAMIX	• <i>Pavblu in Diabetic Retinopathy, US</i>
SPECIAL TOPIX	• Gene Therapies in Retina, US • Pipeline Opportunities in Ophthalmology, US

Cross Specialty

SPECIAL TOPIX	• <i>Payer Management Strategies, US</i>
---------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



B-Cell Malignancies

MARKET DYNAMIX	• Large B-Cell Lymphoma, EU⁺ • Chronic Lymphocytic Leukemia, US⁺
REALTIME DYNAMIX	• Large B-Cell Lymphoma, US⁺
PATIENT CHART DYNAMIX	• Large B-Cell Lymphoma, US⁺ • Chronic Lymphocytic Leukemia, US⁺
PATIENT VOICE DYNAMIX	• B-Cell Malignancies, US⁺

Bleeding Disorders

MARKET DYNAMIX	• Hemophilia, US • Hemophilia, EU5 • Von Willebrand Disease⁺
LAUNCH DYNAMIX	• Hympavzi in Hemophilia A & B • Alhemo in Hemophilia A & B • Qfitlia in Hemophilia A & B
PATIENT CHART DYNAMIX	• Hemophilia A & B⁺
PATIENT VOICE DYNAMIX	• Hemophilia A & B⁺
SPECIAL TOPIX	• Women, Girls, and People who have or had the Potential to Menstruate (WGPPM) and Bleeding Disorders⁺

Hemoglobinopathies

MARKET DYNAMIX	• Sickle Cell Disease, US • Thalassemia, US
LAUNCH DYNAMIX	• Casgevy and Lyfgenia in Sickle Cell Disease and Beta-Thalassemia, US • Mitapivat in Thalassemia⁺⁺
PATIENT CHART DYNAMIX	• Sickle Cell Disease, US • Thalassemia, US
PATIENT VOICE DYNAMIX	• Sickle Cell Disease⁺

Myelodysplastic Syndrome

MARKET DYNAMIX	• Myelodysplastic Syndrome, US⁺
----------------	---

Multiple Myeloma

MARKET DYNAMIX	• Multiple Myeloma, EU5⁺
REALTIME DYNAMIX	• Multiple Myeloma, US
PATIENT CHART DYNAMIX	• Multiple Myeloma, US⁺
PATIENT VOICE DYNAMIX	• Multiple Myeloma, US⁺

Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	• Paroxysmal Nocturnal Hemoglobinuria, EU5
REALTIME DYNAMIX	• Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT CHART DYNAMIX	• Paroxysmal Nocturnal Hemoglobinuria, US

Other Benign Hematology Indications

MARKET DYNAMIX	• Immune Thrombocytopenic Purpura (ITP) • Warm Autoimmune Hemolytic Anemia (w-AIHA)
LAUNCH DYNAMIX	• Nipocalimab in w-AIHA⁺⁺ • Rilzabrutinib in ITP⁺⁺
SPECIAL TOPIX	• Adoption and Impact of Gene Therapy in Hematology • Multispecialty (Nephrology & Hematology) Approach to Atypical Hemolytic Uremic Syndrome (aHUS), US

Cross Specialty


SPECIAL TOPIX	• Payer Management Strategies, US
---------------	---

Multi-Indication

PAYER DYNAMIX	• Cell and Gene Therapy, US⁺
---------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



**Looking for more?
Visit the Spherix Portal**

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

**Create your free account at
www.clientportal.spherixglobalinsights.com**